Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis

Thorax

Volumn 53, Issue 12, 1998, Pages 1014-1017

  Milla, Carlos E ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Box 742 ^*  (United States)

Author keywords

Cystic fibrosis; Disease progression; rhDNase

Indexed keywords

DEOXYRIBONUCLEASE;

ADOLESCENT; ADULT; ARTICLE; CYSTIC FIBROSIS; DISEASE COURSE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; NUTRITIONAL PARAMETERS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SPIROMETRY; UNITED STATES;

EID: 0031701120     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.12.1014     Document Type: Article

References (21)

1. Konstan MW, Berger M. Infection and inflammation of the lung in cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. New York: Marcel Dekker, 1992:219-76.
2. Davis PB, Drumm M, Konstan MW. State of the art: cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-56.
3. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959;24:739-45.
4. Matthews LW, Spector S, Lemm J, et al. Studies on pulmonary secretions. I. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1963; 88:199-204.
5. Armstrong JB, White JC. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet 1950;ii:739.
6. Chernick WS, Barbero GJ, Eichel HJ. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics 1961;27:589-96.
7. Lieberman J. Enzymatic dissolution of pulmonary secretions. Am J Dis Child 1962;104:342-8.
8. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 1968;98:697-9.
9. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-92.
10. Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Respir J 1995;8:1766-91.
11. Hubbard RC, McElvaney NF, Birrer P, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992; 326:812-5.
12. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-51.
13. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
14. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary fucntion in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
15. Shah PL, Scon SF, Geddes DM, et al. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995;89:499-502.
16. Davies J, Trindade MT, Wallis C, et al. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997;23:243-8.
17. Cantin AM. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice. Am J Respir Crit Care Med 1998;157: 464-9.
18. Range SP, Knox AJ. Editorial: rhDNase in cystic fibrosis Thorax 1995;50:321-2.
19. Cramer GW, Bosso JA. The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother 1996;30:656-61.
20. Zach MS. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems. Thorax 1996;51:750-5.
21. Dornase alfa for cystic fibrosis. Drug Ther Bull 1995,33:15-6.